A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome:...

Area of Science:

• Oncology
• Clinical Pharmacology
• Patient-Reported Outcomes

Background:

• Carcinoid syndrome, a rare condition caused by neuroendocrine tumors, significantly impacts patient quality of life.
• Lanreotide is a somatostatin analog used to manage carcinoid syndrome symptoms.
• The ELECT trial (NCT00774930) evaluated the efficacy and safety of lanreotide.

Purpose of the Study:

• To conduct a post hoc analysis of patient-reported outcomes from the ELECT trial.
• To explore the specific effects of lanreotide on carcinoid syndrome symptoms.
• To identify the most clinically meaningful patient-reported outcomes for patients treated with lanreotide.

Main Methods:

• Utilized patient-reported outcomes from the double-blind phase of the placebo-controlled ELECT trial.
• Assessed daily diarrhea and flushing symptoms, octreotide rescue use, and EORTC QLQ-C30/QLQ-GINET21 questionnaires.
• Applied Principal Component (PC) analysis to baseline data to identify key symptom clusters and derive responder analysis criteria.

Main Results:

• Principal Component analysis identified C30 summary score, diarrhea burden, and flushing burden as key domains.
• Lanreotide treatment showed significantly higher improvement rates in C30 summary score (RR 2.42, P=0.023) and diarrhea burden (RR 2.85, P=0.005) compared to placebo.
• Patients on lanreotide demonstrated a trend towards higher response rates in flushing burden (RR 1.39, P=0.31) and overall symptom improvement (RR 1.48, P=0.06).

Conclusions:

• Lanreotide effectively improves diarrhea burden in carcinoid syndrome, aligning with reduced octreotide rescue use.
• This analysis reveals a novel benefit of lanreotide in improving quality-of-life domains beyond symptom control.
• Patient-reported outcomes are crucial for understanding the comprehensive benefits of lanreotide in carcinoid syndrome management.